Pharmaceuticals, Biotechnology and Life Sciences
Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.
Sun Pharmaceutical Industries, largest India-based generic pharmaceutical companies, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Novartis’ Gleevec.
Flood in India’s Chennai suspends operations at Natco Pharma API plant
Savy Akers’ 10,000 square foot production facility in Haikou National Hi-Tech Industrial Zone, Hainan province, is now fully operational.
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
Teva and Takeda are forming a new joint venture to operate in Japan
“Ours will be the last generation to see the horror of children paralyzed or killed by polio. I am sure,” said Pr Jacob John, Former Christian Medical College, Vellore, Tamil Nadu, India.
“Maybe we will remember 2015 as the year we took the final step to eradicate this disease forever.”
RPG Life Science Limited has said that the media reports which said that “RPG Life Plans Skincare Foray, May Roll Out Biz Next Month” came out premature.
GlaxoSmithKline Plc has cut 40 percent of its sales reps in China and axed some units as it eyes a return to growth in 2016, after sales plunged during a bribery scandal that landed it with a record $490 million fine in 2014.